SEC Form 4 · accession 0001123292-18-000972
Innovation Pharmaceuticals Inc. · IPIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur Peter Bertolino
Officer — President and CMO
Period of report
Sep 1, 2018
Accepted (ET)
Sep 24, 2018 · 4:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001355250
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common StockF1 | Sep 1, 2018 | A | 1,066,667 | $0.00 | A | 2,699,873 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $0.398 | Sep 1, 2018 | A | 617,839 | A | — | Sep 1, 2028 | Class A Common Stock | 617,839 | 617,839 | D |
Explanation of responses
- F1The restricted stock and stock options vest upon the earliest of (i) 50% on September 1, 2019 and 50% on September 1, 2020; (ii) the Company's common stock closes above $3.00 per share (as may be adjusted for any stock splits or similar actions); (iii) the commencement of trading of the Company's common stock on a national securities exchange; or (iv) upon a change of control of the Company, as defined in the Company's 2016 Equity Incentive Plan.